First Tracks Shares Climb Ahead of Early-Stage Trial Readout
Dow Jones
Oct 12
Shares of First Tracks Biotherapeutics were higher after the company said it would review top-line data from a trial of its treatment for celiac disease on Monday.
The stock rose 15%, to $36.71, in premarket trading. Through Friday's close, shares are up nearly 68% year to date.
The company said late Friday that it will host an investor call and live webcast to review top-line data from the first cohort of an early-stage trial investigating its drug, ANB033, as a treatment for celiac disease.
The call and webcast are scheduled for 8:30 a.m. Eastern on Monday.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.